Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial

Highest dose of tirzepatide reduced A1C by 2.58 percent and body weight by 11.7 kg (25.8 lb., 13.0 percent) SURPASS program has now met regulatory submission requirements for evaluating cardiovascular risk; Lilly intends to submit registration package to regulatory authorities by the end of 2021